Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Montreal's Ventus Therapeutics

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Sep 29, 2022 3:28pm

100 Views

Post# 34995711

RE:RE:RE:RE:RE:RE:RE:RE:Montreal's Ventus Therapeutics

And yet they keep talking about it and haven't abandoned it. Maybe they are selling more Egrifta to the doctors who are like, what the heck, might as well try for a double whammy solution to both issues in my HIV patients.

longterm56 wrote: If there is not enough interest in Egrifta for NASH to generate a partnership, do you really want THTX to go it alone? I'm sure big pharma has looked at it and has said, "no thanks". So why would they pursue it?

Lee430 wrote: If we did not have this potential high reward cancer platform would Thera have kept their eyes on the NASH prize and it would maybe be in PH3 by now instead of sending it to the time out chair?

Biobob wrote: I understand the frustration since I share it on a daily basis since 1998. I wprobably wont happen but we can hope a business update on October 13 delivers soemthing that makes Paul seemingly more verbal about Th1902...